Myotonia congenita (Thomsen disease / Becker type)Myotonia Congenita (Thomsen / Becker Type)
📋 Contents and key points
| Item | Details |
| A. Classification codes | ICD-10: G71.1 | Special Copayment Reduction: V012 | Registration validity period: 5 years |
| B. Synonyms | Myotonia congenita NOS, recessive [Becker] myotonia congenita, dominant [Thomsen] myotonia congenita, Myotonia Congenita, Thomsen disease, Becker myotonia |
| C. Adult onset | Likelihood of first onset in adulthood: low — The Thomsen type first presents in infancy to childhood and the Becker type in childhood to adolescence, but some cases go unrecognized until adulthood. |
| 1. History | Go to section |
| 2. Causes | Go to section |
| 3. Genetics | Go to section |
| 4. General epidemiology | Go to section |
| 5. Pathophysiology | Go to section |
| 6. Symptoms | Go to section |
| 7. Signs | Go to section |
| 8. Screening | Go to section |
| 9. Diagnosis | Go to section |
| 10. Treatment | Go to section |
| 11. Prognosis | Go to section |
| 12. Prevention | Go to section |
| 13. References | Go to section |
1. History
Myotonia congenita became known to medicine in 1876 when the Danish physician Julius Thomsen first described in detail the muscle stiffness affecting himself and four generations of his family. Thomsen himself had the disease, and by introducing the term 'myotonia congenita' he first named it as a hereditary disease characterized by delayed muscle relaxation after voluntary movement. From the late 19th to the early 20th century, neurologists refined the clinical description. In 1971, the German Peter Emil Becker described a more severe form of myotonia not previously reported, characterized by a recessive pattern of inheritance and accompanied by transient weakness and muscle hypertrophy. This came to be called the Becker type, or recessive myotonia congenita. The molecular genetic basis was revealed in 1992 by Koch et al., who established that mutations of the CLCN1 gene (chloride channel gene) cause both forms. Since then, more than 300 pathogenic CLCN1 variants have been reported, confirming that variants of the same gene can produce dominant or recessive phenotypes.
2. Causes
Myotonia congenita is caused by pathogenic variants of the CLCN1 gene (7q34), which encodes the main chloride channel of skeletal muscle. The ClC-1 chloride channel plays a key role in normal repolarization of the muscle cell membrane, and loss of function of this channel causes hyperexcitability of the muscle cell membrane, producing myotonia, in which relaxation after voluntary contraction is delayed.
- Dominant form (Thomsen disease): CLCN1 variants act in a dominant-negative manner, so a single variant allele is enough to sufficiently impair ClC-1 channel function. Because ClC-1 functions as a homodimer, overall channel function is reduced when a mutant monomer combines with a normal monomer.
- Recessive form (Becker type): Loss-of-function variants must be present in both alleles for disease to develop. Carriers of a single variant have no clinical symptoms. The Becker type tends to be more prevalent than the Thomsen type and to have more severe clinical symptoms.
More than 300 pathogenic CLCN1 variants have been reported to date, including various variant types such as missense, nonsense, splicing, and small insertions/deletions. Some variants have been reported in both the dominant and recessive forms, making the genotype-phenotype correlation complex.
3. Genetics
Myotonia congenita is caused by pathogenic variants of the CLCN1 gene (7q34). Depending on the nature of the variant, the mode of inheritance is either autosomal dominant (Thomsen type) or autosomal recessive (Becker type).
| Characteristics | Thomsen type (dominant) | Becker type (recessive) |
| Mode of inheritance | Autosomal dominant | Autosomal recessive |
| Age of onset | Infancy to childhood | Childhood to adolescence |
| Clinical severity | Mild to moderate | Moderate to severe |
| Weakness | Rare | Transient weakness characteristic |
| Muscle hypertrophy | Mild | Marked muscle hypertrophy possible |
| Prevalence | About 1/400,000 | About 1/25,000 |
Some CLCN1 variants have incomplete penetrance, so phenotypic diversity is observed even within the same family. In particular, some dominant-form variants show sex differences in penetrance, sometimes with higher penetrance in males. Genetic testing helps predict the mode of inheritance based on variant location and type, but it is difficult to fully predict the clinical outcome of individual variants.
4. General epidemiology
Myotonia congenita is a rare genetic disease, with a worldwide prevalence of both forms combined estimated at about 1/100,000. The Becker type (recessive) is more prevalent than the Thomsen type (dominant), reported at about 1/25,000–1/50,000. The prevalence of the Thomsen type is about 1/400,000. Prevalence is known to be higher in Scandinavian countries (especially Denmark and Finland) than in other regions, which may be related to a founder effect. Prevalence by sex is similar in men and women for both forms, but with some variants of the dominant form, men tend to show a more severe phenotype. Domestic incidence data are limited, but the Becker type is diagnosed more frequently in clinical practice.
5. Pathophysiology
ClC-1 (the CLCN1 gene product) is the main chloride channel, responsible for about 75–80% of the resting conductance of the skeletal muscle cell membrane. Normally, after a muscle action potential, ClC-1 channels open and chloride ions flow into the cell, stabilizing (repolarizing) the membrane potential.
When ClC-1 channel conductance decreases due to CLCN1 loss-of-function variants, the muscle cell membrane is placed in a hyperexcitable state. As a result, repetitive action potentials occur continuously even after a single voluntary contraction stimulus (sustained depolarization), resulting in myotonia, in which the muscle cannot relax. The transient weakness observed in the Becker type is understood to be related to cumulative inactivation of sodium channels due to repetitive action potentials.
The warm-up phenomenon (easing of myotonia with repeated exercise) is explained by a mechanism in which extracellular potassium ion concentration rises as muscle activity is repeated, contributing to ClC-1 channel activation and membrane potential stabilization.
6. Symptoms
The core symptom of myotonia congenita is myotonia, an abnormal delay in relaxation after voluntary muscle contraction. Skeletal muscles throughout the body are involved, especially prominently the muscles of the lower limbs, upper limbs, face, and tongue.
Myotonic symptoms
- Muscle stiffness: Most severe with the first movement after rest; the warm-up phenomenon, in which it improves with continued exercise, is characteristic. Especially severe right after waking in the morning and when standing up after sitting for a long time.
- Difficulty initiating movement: When suddenly running or starting a quick movement, movement is limited by stiffness for several seconds.
- Facial myotonia: Difficulty opening the eyes after squeezing them shut. Delayed blinking after exposure to bright light.
- Worsening with cold: Myotonia intensifies in cold environments and improves in warm environments.
- Emotional stimuli: Symptoms may worsen with sudden startle or stress.
Symptoms specific to the Becker type
- Transient weakness: A feature seen only in the Becker type, in which severe weakness on the first movement lasts several seconds to minutes and then recovers. A major cause of fall risk.
- Muscle hypertrophy: Muscle hypertrophy due to sustained muscle contraction is observed, especially in the lower limbs. Patients may look like they have an 'athletic build'.
Impact on quality of life
- Limitation of exercise, restrictions on career choice, difficulty with social participation.
- Risk of accidents such as falls without prior awareness of myotonia.
- Pain: some patients complain of muscle pain.
7. Signs
Myotonia-related signs
- Percussion myotonia: Tapping the thenar eminence, tongue, or deltoid with a reflex hammer produces a local muscle contraction lasting several seconds. Particularly marked in myotonia congenita.
- Eyelid myotonia: When asked to open the eyes after squeezing them shut, eye opening is delayed.
- Grip myotonia: Delayed finger extension after a handshake. Improvement with repetition due to the warm-up phenomenon is characteristic of the Thomsen/Becker types (a point of differentiation from paramyotonia).
Muscle hypertrophy and body habitus
- In the Becker type in particular, hypertrophy of the lower-limb muscles (especially the gastrocnemius and quadriceps) is observed, resembling an athletic build.
- Mild muscle hypertrophy may also appear in the Thomsen type.
Laboratory findings
- Serum CK: normal or mildly elevated. Tends to be higher in the Becker type.
- EMG: characteristic myotonic discharges — increased insertional activity, spontaneous myotonic discharges (dive-bomber pattern).
Other
- Cardiac, ocular, endocrine, and cognitive function are normal — an important point of differentiation from myotonic dystrophy (DM1/DM2).
8. Screening
- Clinical history: Check for muscle stiffness beginning in childhood, the warm-up phenomenon, family history (dominant form), and worsening with cold.
- Serum CK: Normal or mildly elevated. A normal CK does not exclude the diagnosis.
- Electromyography (EMG): Confirmation of myotonic discharges — key to screening and diagnosis. Observation of percussion myotonia. Pure myotonic discharges without neuropathic findings on EMG.
- Short exercise test: Measurement of the compound muscle action potential (CMAP) after brief exercise, used to screen for myotonic channelopathies and distinguish their types.
- Family history: In the dominant form, family history is clear, so check whether family members have symptoms.
9. Diagnosis
The disease is suspected from clinical symptoms and EMG findings and confirmed by molecular genetic testing of the CLCN1 gene.
Molecular genetic testing
- CLCN1 gene sequencing: identification of pathogenic variants. More than 300 known variants have been reported, and novel variants continue to be reported.
- Gene panel testing: simultaneous analysis of genes related to ion channelopathies (CLCN1, SCN4A, CACNA1S, KCNJ2, etc.).
Ancillary diagnosis
- EMG: confirmation of myotonic discharges (essential). Increased insertional activity, characteristic dive-bomber pattern.
- Short/long exercise test: CMAP analysis helps distinguish ClC-1 channelopathy from Na channelopathy.
- Muscle biopsy: generally nonspecific findings (muscle hypertrophy, mild variation in fiber size). Performed only when diagnosis by genetic testing is difficult.
Differential diagnosis
- Myotonic dystrophy (DM1/DM2): differentiated by multiorgan involvement, genetic anticipation, cataracts, and cardiac conduction defects.
- Paramyotonia Congenita (SCN4A variants): differentiated by worsening of myotonia with exercise followed by progression to paralysis, and no improvement with warm-up.
- Schwartz-Jampel syndrome: accompanied by skeletal abnormalities.
- Hyperkalemic periodic paralysis: episodic paralysis with myotonia, SCN4A variants.
10. Treatment
Myotonia congenita is not life-threatening, and the goals of treatment are relief of myotonic symptoms and improvement in quality of life.
Drug therapy
- Mexiletine: Currently the first-choice drug with the strongest evidence. Reduces muscle membrane hyperexcitability through sodium channel blockade. Adult dose: 150–200 mg 2–3 times daily (maximum 900 mg/day). The CINCH trial demonstrated a significant reduction in myotonia compared with placebo. Adverse effects: nausea, dizziness, cardiac arrhythmia (caution in patients with cardiac conduction abnormalities).
- Lamotrigine: Second choice when mexiletine is not tolerated. Sodium channel-blocking mechanism. Efficacy reported in small studies.
- Carbamazepine: A traditionally used sodium channel blocker. Used with consideration of its adverse effect profile.
- Phenytoin, procainamide: Can be used but are currently less preferred.
- Acetazolamide: Effective in some patients, but the evidence in myotonia congenita is weaker than in paramyotonia.
Non-pharmacological treatment
- Regular warm-up: symptoms are reduced with sufficient warm-up before activity.
- Minimize exposure to cold environments: management of clothing and environment to prevent worsening with cold.
- Adjust planning of work and daily activities: avoid sudden movements and start activities gradually.
- Physical therapy: exercise programs for strengthening and maintaining function.
Anesthetic management
- Use of a depolarizing muscle relaxant (succinylcholine) can trigger sustained muscle contraction (myotonic crisis) — contraindicated or used with extreme caution.
- Maintenance of body temperature during surgery is essential to prevent cold-induced worsening of myotonia.
11. Prognosis
Myotonia congenita is a non-progressive disease without life-threatening complications and is not accompanied by serious visceral involvement or cognitive impairment. Most patients have a normal life span, and symptoms can be adequately controlled with appropriate treatment. The myotonia itself may improve somewhat with age but rarely disappears completely. The Becker type has more severe symptoms than the Thomsen type, with a risk of accidents such as falls due to transient weakness, but it does not progress to long-term weakness or muscle atrophy. Persistent mild weakness in adulthood has also been reported in some patients with the Becker type. Symptoms may change during pregnancy, and transient myotonic symptoms may appear in newborns.
12. Prevention
- Genetic counseling: The Thomsen type (dominant) is transmitted from an affected parent with a 50% probability. The Becker type (recessive) has a 25% probability when both parents are carriers. Genetic counseling is provided to the family after molecular confirmation.
- Preimplantation genetic diagnosis (PGT-M): Can be chosen before conception in affected families.
- Prenatal diagnosis: Prenatal diagnosis is possible in families with a known variant.
- Avoiding exacerbating factors: Refrain from exposure to extreme cold and sudden strenuous exercise.
- Notification before surgery and anesthesia: Inform the anesthesia team in advance of the diagnosis and the contraindication to depolarizing muscle relaxants.
- Education and self-management: Educate patients and caregivers on the warm-up principle, fall prevention, and avoiding cold.
13. References
- Koch MC, Steinmeyer K, Lorenz C, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science. 1992;257(5071):797–800. PMID: 1379744
- Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018;57(4):522–530. PMID: 28846808
- Trip J, Drost G, van Engelen BG, Faber CG. Drug treatment for myotonia. Cochrane Database Syst Rev. 2006;(1):CD004762. PMID: 16437491
- Stunnenberg BC, Raaphorst J, Groenewoud HM, et al. Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials. JAMA. 2018;320(22):2344–2353. PMID: 30535218
- Colding-Jorgensen E. Phenotypic variability in myotonia congenita. Muscle Nerve. 2005;32(1):19–34. PMID: 15880415
- Fialho D, Bhatt DL, Hanna MG, et al. Non-dystrophic myotonias: a consensus guide to diagnosis and management. Pract Neurol. 2018;18(6):484–498. PMID: 29959219
- Suetterlin K, Männikkö R, Hanna MG. Complex phenotype in patients with CLCN1 mutations. Neurology. 2017;88(14):1310–1317. PMID: 28275018
- Orhan Sencer G, Bulut NI, Durmus H, et al. Clinical and genetic analysis and literature review of children with myotonia congenita due to CLCN1 mutations. Eur J Paediatr Neurol. 2025. PMC12150482
- Kuntzer T, Flocard F, Vial C, et al. Exercise test in muscle channelopathies and other muscle disorders. Muscle Nerve. 2000;23(7):1089–1094. PMID: 10882998
- Moxley RT 3rd, Logigian EL, Martens WB, et al. Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonia congenita. Muscle Nerve. 2007;36(3):320–328. PMID: 17566114